Anti‐CD47‐PCM@NP exhibited significantly greater suppressions on the average tumor sizes compared to the anti‐CD47 group and PCM@NP control group (Figure S18, Supporting Information), with an approximately twofold tumor inhibition rate compared with the anti‐CD47 group on day 19. Here, CD47 is linked to neoplasm.